NO972909L - Substituerte azetidin-2-oner for behandling av atherosklerose - Google Patents

Substituerte azetidin-2-oner for behandling av atherosklerose

Info

Publication number
NO972909L
NO972909L NO972909A NO972909A NO972909L NO 972909 L NO972909 L NO 972909L NO 972909 A NO972909 A NO 972909A NO 972909 A NO972909 A NO 972909A NO 972909 L NO972909 L NO 972909L
Authority
NO
Norway
Prior art keywords
atherosclerosis
treatment
ones
substituted azetidin
alkyl
Prior art date
Application number
NO972909A
Other languages
English (en)
Other versions
NO972909D0 (no
Inventor
Deirdre Mary Bernadette Hickey
Colin Andrew Leach
Robert John Ife
David Graham Tew
Dashyant Dhanak
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9426020.5A external-priority patent/GB9426020D0/en
Priority claimed from GBGB9426030.4A external-priority patent/GB9426030D0/en
Priority claimed from GBGB9511599.4A external-priority patent/GB9511599D0/en
Priority claimed from GBGB9511600.0A external-priority patent/GB9511600D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO972909D0 publication Critical patent/NO972909D0/no
Publication of NO972909L publication Critical patent/NO972909L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Forbindelser med formel (I): R' r S(0)nR \ CH, x-Y hvor; (1) R'' og r2, som kan være like eller forskjellige, hver er valgt fra hydrogen, halogen eller C(i.g)alkyl; r3 er aryl eller arylC(i_4)alkyl som kan være eventuelt substituert; X er en forbindende gruppe; Y er en eventuelt substituert arylgruppe; og n er 0, 1 eller 2; er hemmere av enzymet Lp-PL^2 og kan derfor anvendes ved behandling av atherosklerose.
NO972909A 1994-12-22 1997-06-20 Substituerte azetidin-2-oner for behandling av atherosklerose NO972909L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9426020.5A GB9426020D0 (en) 1994-12-22 1994-12-22 Novel compounds
GBGB9426030.4A GB9426030D0 (en) 1994-12-23 1994-12-23 Novel compounds
GBGB9511599.4A GB9511599D0 (en) 1995-06-08 1995-06-08 Novel compounds
GBGB9511600.0A GB9511600D0 (en) 1995-06-08 1995-06-08 Novel compounds
PCT/EP1995/005130 WO1996019451A1 (en) 1994-12-22 1995-12-20 Substituted azetidin-2-ones for treatment of atherosclerosis

Publications (2)

Publication Number Publication Date
NO972909D0 NO972909D0 (no) 1997-06-20
NO972909L true NO972909L (no) 1997-08-20

Family

ID=27451242

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972909A NO972909L (no) 1994-12-22 1997-06-20 Substituerte azetidin-2-oner for behandling av atherosklerose

Country Status (24)

Country Link
US (1) US5990102A (no)
EP (1) EP0799200A1 (no)
JP (1) JPH11500415A (no)
CN (1) CN1175246A (no)
AP (1) AP9701007A0 (no)
AR (1) AR002012A1 (no)
AU (1) AU704407B2 (no)
BG (1) BG101687A (no)
BR (1) BR9510420A (no)
CA (1) CA2208530A1 (no)
CZ (1) CZ192297A3 (no)
DZ (1) DZ1958A1 (no)
FI (1) FI972584A7 (no)
HU (1) HUT77089A (no)
IL (1) IL116485A0 (no)
MA (1) MA23834A1 (no)
MX (1) MX9704736A (no)
NO (1) NO972909L (no)
NZ (1) NZ298416A (no)
OA (1) OA10737A (no)
PL (1) PL320937A1 (no)
SK (1) SK80397A3 (no)
TR (1) TR199501655A2 (no)
WO (1) WO1996019451A1 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515852A (ja) * 1995-07-01 2002-05-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のためのアゼチジノン誘導体
WO1997021676A1 (en) * 1995-12-08 1997-06-19 Smithkline Beecham Plc Azetidinone compounds for the treatment of atherosclerosis
WO1997021675A1 (en) * 1995-12-08 1997-06-19 Smithkline Beecham Plc Monocyclic beta-lactame derivatives for treatment of atherosclerosis
GB9608649D0 (en) * 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
NZ332476A (en) * 1996-04-26 2000-06-23 Smithkline Beecham Plc substituted 4-(carboxybenzylsulphinyl)-2-oxo-azetidine derivatives
AU4654199A (en) * 1998-07-23 2000-02-14 Shionogi & Co., Ltd. Monocyclic beta-lactam compounds and chymase inhibitors containing the same
EP1686119B1 (en) 2000-02-16 2009-07-29 Smithkline Beecham Plc Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CA2517572C (en) 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) * 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2005107767A2 (en) * 2004-05-03 2005-11-17 Ilypsa, Inc. Modulation of lysophosphatidylcholine and treatment of diet-induced conditions
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
AU2008251467B2 (en) 2007-05-11 2014-07-31 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
CN101986785A (zh) 2007-05-11 2011-03-16 托马斯杰弗逊大学 治疗和预防神经退行性疾病和紊乱的方法
PE20140421A1 (es) 2010-12-06 2014-04-26 Glaxo Group Ltd COMPUESTOS DERIVADOS DE PIRIMIDINONA COMO INHIBIDORES DE Lp-PLA2
EP2651403B1 (en) 2010-12-17 2020-12-02 Glaxo Group Limited Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
WO2013000267A1 (zh) 2011-06-27 2013-01-03 中国科学院上海药物研究所 唑类杂环化合物、其制备方法、药物组合物和用途
AR087309A1 (es) 2011-07-27 2014-03-12 Glaxo Group Ltd Compuesto heterociclico de anillos condensados sustituido, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades neurogenerativas y aterosclerosis
EP2739627A4 (en) 2011-07-27 2015-01-21 Glaxo Group Ltd 2,3-DIHYDROIMIDAZO [1,2-C] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AND USE AS INHIBITORS OF LP-PLA2
EP2948452B1 (en) 2013-01-25 2017-08-09 GlaxoSmithKline Intellectual Property Development Limited 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors
BR112015017768A2 (pt) 2013-01-25 2017-07-11 Glaxosmithkline Ip Dev Ltd compostos
AU2014210260B2 (en) 2013-01-25 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2
WO2015179293A1 (en) * 2014-05-18 2015-11-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Small molecule activators and inhibitors of lecithin: cholesterol acyltransferase
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN112778331B (zh) 2019-11-09 2022-07-05 上海赛默罗生物科技有限公司 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途
TWI896037B (zh) 2023-07-17 2025-09-01 大陸商上海樞境生物科技有限公司 雙環[5,6]咪唑嘧啶酮類衍生物、其製備方法和應用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0010358A1 (en) * 1978-09-20 1980-04-30 Glaxo Group Limited Beta-lactam compounds, processes for their preparation, compositions containing them, intermediates of use in their preparation and methods for the production thereof
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
DZ1958A1 (fr) 2002-02-17
AR002012A1 (es) 1998-01-07
US5990102A (en) 1999-11-23
JPH11500415A (ja) 1999-01-12
NZ298416A (en) 1999-03-29
CZ192297A3 (en) 1997-11-12
TR199501655A2 (tr) 1996-07-21
PL320937A1 (en) 1997-11-10
CN1175246A (zh) 1998-03-04
MX9704736A (es) 1997-10-31
FI972584L (fi) 1997-08-19
MA23834A1 (fr) 1996-10-01
CA2208530A1 (en) 1996-06-27
BR9510420A (pt) 2004-04-20
NO972909D0 (no) 1997-06-20
FI972584A0 (fi) 1997-06-17
AU4389896A (en) 1996-07-10
BG101687A (bg) 1998-02-27
HUT77089A (hu) 1998-03-02
OA10737A (en) 2002-12-10
FI972584A7 (fi) 1997-08-19
AP9701007A0 (en) 1997-07-31
WO1996019451A1 (en) 1996-06-27
AU704407B2 (en) 1999-04-22
SK80397A3 (en) 1998-01-14
EP0799200A1 (en) 1997-10-08
IL116485A0 (en) 1996-08-04

Similar Documents

Publication Publication Date Title
NO972909L (no) Substituerte azetidin-2-oner for behandling av atherosklerose
NO976158L (no) Azetidinon-derivater for behandling av atherosklerose
NO982913L (no) Kinolin- og kinazolinforbindelser nyttige i terapi
NO984939L (no) Azetidinon-derivater for behandling av atherosklerose
TW341573B (en) New erythromycin derivatives, their preparation process and their use as medicaments
ATE128143T1 (de) 17-beta-substituierte-4-aza-5-alpha-androstan-3 one-derivate und verfahren zu ihrer herstellung.
DE69705480D1 (de) Verwendung von Oestrogenagonisten und -antagonisten zur Herstellung eines Medikaments zur Behandlung von Atherosklerose, unabhängig von Lipidsenkung
DE69607650D1 (de) 2,3,5-trimethyl-hydroxyanilid-derivative, ihre herstellung und ihre theraoeutische verwendung
ATE109768T1 (de) Verfahren zur enantioselektiven herstellung von phenylisoserinderivaten.
YU89691A (sh) Postupak za dobijanje stereoselektivnih derivata fenilizoserina
ATE207929T1 (de) Diastereomerenreine 3-oxo und 3-thioxo-4-aza- androstanderivate und ihre verwendung als antiandrogene
MX9800412A (es) Preparacion de 3-hidroxipirazoles n-substituidos.
ATE143976T1 (de) Verfahren zur silylierung von kohlenhydraten und verwendung der silylierten kohlenhydrate
NO955326L (no) Isokinolinderivater, fremgangsmåte for deres fremstilling og terapeutiske anvendelse
DK0852580T3 (da) Fremgangsmåde til fremstilling af dihydroxypyrimidin-derivater
HU9502184D0 (en) Optically active beta-aminoalkoxyborane complex
ATE186961T1 (de) Verfahren zur behandlung von cellulosefasern und von gebilden aus diesen fasern
DE69719511D1 (de) Antivirale 2,4-pyrimidindion-derivate und verfahren zu ihrer herstellung
DE3867073D1 (de) Allylmercaptoacetyl-sydnonimine, verfahren zu ihrer herstellung und ihre verwendung.
NO983283L (no) Hydrokamsyre-baserte Kollagenase-inhibitorer
TW336288B (en) Phenylenediamine derivative and electrophotosensitive material using the same
NO964522L (no) Fremgangmåte ved fremstilling av 5,6-dihydroksy-2-amino-1,2,3,4-tetrahydronaftalenderivater
FI915025A0 (fi) 8-azabicyklo(3,2,1) oktylalkyltiazolidinoner, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
NO964735L (no) Adenosin-derivater
TR199801683A2 (xx) Yeni �re t�revleri.